Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Year	2023	2022	2021	2020	2019
Revenue	107.4	96.67	65.63	27.63	7.32
Revenue Growth (YoY)	11.10%	47.29%	137.52%	277.47%	100.00%
Cost of Revenue	40.77	44.39	36.43	8.28	2.2
Gross Profit	66.63	52.28	29.2	19.35	5.12
Selling, General & Admin	70.08	69.88	55.81	31.06	19.24
Research & Development	4.1	12.66	5.62	1.72	0.59
Other Operating Expenses	10.49	81.3	26.64	7.7	2.14
Operating Expenses	84.67	163.84	88.07	40.48	21.96
Operating Income	-18.03	-111.56	-58.87	-21.13	-16.85
Other Expense / Income	-0.98	-2.67	-0.84	-7.51	10.29
Pretax Income	-17.05	-108.89	-58.03	-13.62	-27.13
Income Tax	0	-0.11	0.26	0	0
Net Income	-17.05	-108.78	-58.29	-13.62	-27.13
Shares Outstanding (Basic)	3	1	1	0	0
Shares Outstanding (Diluted)	3	1	1	0	0
Shares Change	127.22%	75.54%	270.57%	479.80%	1071.03%
EPS (Basic)	-5.11	-74.01	-69.60	-60.20	-696.00
EPS (Diluted)	-5.11	-74.01	-69.60	-60.20	-696.00
Free Cash Flow	-5.13	-28.82	-25.96	-28.37	-13.89
Free Cash Flow Per Share	-1.54	-19.61	-31.01	-125.57	-356.44
Gross Margin	62.04%	54.08%	44.49%	70.03%	69.92%
Operating Margin	-16.79%	-115.41%	-89.70%	-76.47%	-230.13%
Profit Margin	-15.88%	-112.53%	-88.81%	-49.29%	-370.64%
Free Cash Flow Margin	-4.78%	-29.82%	-39.56%	-102.69%	-189.76%
EBITDA	-8.24	-98.74	-48.83	-7.91	-24.4
EBITDA Margin	-7.67%	-102.15%	-74.40%	-28.62%	-333.38%
Depreciation & Amortization	8.82	10.15	9.2	5.71	2.73
EBIT	-17.05	-108.89	-58.03	-13.62	-27.13
EBIT Margin	-15.88%	-112.64%	-88.42%	-49.29%	-370.64%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).